Seattle-based Omeros Corporation is a commercial-stage biopharmaceutical company that specializes in discovering, developing and commercializing small-molecule and protein therapeutics to treat a range of conditions, including inflammation, cancers related to immune system dysfunction, and addictive and compulsive disorders. Its preclinical and clinical programs focus on developing drugs to treat rare orphan indications, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria. Omeros Corporation has been in operation since 1994.